Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep's Potential in Colorectal CancerGlobeNewsWire · 5 days ago
Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant PaymentGlobeNewsWire · Oct 14, 2026
Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio UpdateGlobeNewsWire · Oct 12, 2026
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to ImmunotherapyGlobeNewsWire · Sep 29, 2026
Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer StudyGlobeNewsWire · Sep 28, 2026
Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal CancerGlobeNewsWire · Sep 10, 2026Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.05 | -$0.08 | Miss |
| May 14, 2026 | -$0.05 | -$0.08 | Miss |
| Mar 30, 2026 | -$0.06 | -$0.01 | Beat |
| Nov 12, 2025 | -$0.12 | -$0.10 | Beat |
| Aug 8, 2025 | -$0.11 | -$0.05 | Beat |
| May 14, 2025 | -$0.09 | -$0.06 | Beat |